Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
PR Newswire•30/07/2026•16:06 ET
0
Whiz Insights
Get started
Create a free account to read the full story.
Create a free account to read the full story.